已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial

医学 阿帕蒂尼 临床终点 内科学 无进展生存期 胎盘部位滋养细胞肿瘤 肿瘤科 化疗 临床研究阶段 临床试验 外科 怀孕 胎儿 遗传学 生物 胎盘
作者
Hongyan Cheng,Liju Zong,Yujia Kong,Xiaoyu Wang,Yu Gu,Wei Cang,Jun Zhao,Xirun Wan,Junjun Yang,Yang Xiang
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (11): 1609-1617 被引量:53
标识
DOI:10.1016/s1470-2045(21)00460-5
摘要

Summary

Background

Treatment options for patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia are scarce. The synergistic antitumour effect of immunotherapy and antiangiogenic drugs has been shown in many solid tumours. This phase 2 trial evaluated the activity and safety of camrelizumab (PD-1 inhibitor) plus apatinib (VEGF receptor inhibitor) in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.

Methods

This was a single-arm, open-label, phase 2 trial, done at a single tertiary health-care centre in Beijing, China. Women (18–70 years) with high-risk (International Federation of Gynecology and Obstetrics score ≥7) chemorefractory or relapsed gestational trophoblastic neoplasia who had received at least two lines of previously unsuccessful multidrug chemotherapy regimens and had an Eastern Cooperative Oncology Group performance status of 0–2 were eligible for inclusion. Patients received 4-week cycles of intravenous camrelizumab 200 mg every 2 weeks plus oral apatinib 250 mg once per day until disease progression or unacceptable toxicity. The primary endpoint was objective response rate assessed according to serum human chorionic gonadotrophin concentration. Activity and safety were analysed in all patients who received at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov, NCT04047017.

Findings

Between Aug 7, 2019, and March 18, 2020, 20 patients enrolled; 19 (95%) were diagnosed with choriocarcinoma and one (5%) had placental site trophoblastic tumour. The median follow-up duration was 18·5 months (IQR 14·6–20·9). The objective response rate was 55% (95% CI 32–77); ten (50%; 95% CI 27–73) patients had complete response. The most common grade 3 treatment-related adverse events were hypertension (five [25%] patients), rash (four [20%] patients), neutropenia (two [10%]), leukocytopenia (two [10%]), and aspartate aminotransferase increase (two [10%]). One patient had a treatment-related serious adverse event (aspartate aminotransferase 19-times higher than the upper limit of normal). No grade 4 or 5 treatment-related adverse events were reported.

Interpretation

Camrelizumab plus apatinib showed promising antitumour activity and acceptable toxicity and could be a salvage therapy option for the treatment of high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Immune checkpoint inhibitors combined with chemotherapy for heavily-treated patients and upfront use of camrelizumab plus apatinib for patients with high-risk gestational trophoblastic neoplasia are under investigation in phase 2 trials.

Funding

National Natural Science Foundation of China, Jiangsu Hengrui Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
W2026完成签到,获得积分10
2秒前
Singularity应助小米采纳,获得10
2秒前
xuliping发布了新的文献求助10
3秒前
明亮剑完成签到 ,获得积分10
4秒前
科研小学生完成签到,获得积分10
4秒前
科研通AI2S应助sing采纳,获得30
5秒前
包容的绝义完成签到,获得积分10
6秒前
爆米花应助钮小童采纳,获得10
7秒前
7秒前
scigo完成签到,获得积分10
9秒前
11秒前
酷炫果汁完成签到 ,获得积分10
13秒前
liweiDr发布了新的文献求助10
15秒前
小丘2024发布了新的文献求助10
20秒前
25秒前
26秒前
科研通AI2S应助盛夏如花采纳,获得10
28秒前
恰同学少年完成签到,获得积分10
29秒前
32秒前
缓慢的冬云完成签到,获得积分10
35秒前
Dana完成签到 ,获得积分10
36秒前
李龙波完成签到,获得积分10
37秒前
Owen应助樊川采纳,获得10
41秒前
研友_VZG7GZ应助坚强擎汉采纳,获得10
41秒前
43秒前
44秒前
李健应助liweiDr采纳,获得10
45秒前
46秒前
勤劳的星月完成签到 ,获得积分10
48秒前
咕噜噜发布了新的文献求助10
49秒前
49秒前
拼搏思菱发布了新的文献求助10
49秒前
樊川发布了新的文献求助10
52秒前
52秒前
SCI发布了新的文献求助10
54秒前
54秒前
可靠的念柏应助咕噜噜采纳,获得10
57秒前
Jasper应助咕噜噜采纳,获得10
57秒前
小白白发布了新的文献求助10
57秒前
59秒前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139334
求助须知:如何正确求助?哪些是违规求助? 2790231
关于积分的说明 7794518
捐赠科研通 2446658
什么是DOI,文献DOI怎么找? 1301314
科研通“疑难数据库(出版商)”最低求助积分说明 626124
版权声明 601109